Lymphocytic Leukemia, Chronic Clinical Trials

A listing of Lymphocytic Leukemia, Chronic medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

Alta Bates Summit Medical Center
Berkeley California

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

City of Hope National Medical Center
Duarte California

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

University of California Irvine
Irvine California

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

UC San Diego Moores Cancer Center
La Jolla California

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

UCLA Hematology/Oncology
Los Angeles California

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

View More ▼

Duarte California 91010

Patients are needed to participate in a clinical research study evaluating BTCT4465A and Obinutuzumab for the treatment of Lymphocytic Leukemia, Chronic or Lymphoma, Non Hodgkin

La Jolla California 92093

A clinical trial seeking patients for a research study for the treatment of Chronic Lymphocytic Leukemia

Colorado

Denver Colorado 80218

A clinical trial seeking patients for a research study for the treatment of Chronic Lymphocytic Leukemia

Connecticut

New Haven Connecticut 06510

Patients are needed to participate in a clinical research study evaluating BTCT4465A and Obinutuzumab for the treatment of Lymphocytic Leukemia, Chronic or Lymphoma, Non Hodgkin

District of Columbia

Georgetown University Medical Center
Washington District of Columbia

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Florida

Mayo Clinic Jacksonville
Jacksonville Florida

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

H Lee Moffitt Cancer Center and Research Institute
Tampa Florida

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Illinois

Ingalls Memorial Hospital
Harvey Illinois

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Illinois Cancer Care
Peoria Illinois

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Indiana

Indiana University Health Arnett Inc
Lafayette Indiana

ACE-CL-007: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

Kansas

Cancer Center of Kansas
Wichita Kansas

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Minnesota

Mayo Clinic
Rochester Minnesota

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

CentraCare Health
St. Cloud Minnesota

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Park Nicollet Institute
St. Louis Park Minnesota

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Missouri

St. Louis Missouri 63110

Patients are needed to participate in a clinical research study evaluating BTCT4465A and Obinutuzumab for the treatment of Lymphocytic Leukemia, Chronic or Lymphoma, Non Hodgkin

Montana

Frontier Cancer Center and Blood Institute
Billings Montana

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

New Jersey

Hunterdon Regional Cancer Center
Flemington New Jersey

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Hackensack University Medical Center
Hackensack New Jersey

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

New York

Clinical Research Alliance Inc
Lake Success New York

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Long Island Jewish Medical Center
New Hyde Park New York

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Icahn School of Medicine at Mount Sinai
New York New York

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Columbia University Medical Center
New York New York

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Weill Cornell Medical College
New York New York

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

View More ▼

Buffalo New York 14263

A clinical trial seeking patients for a research study for the treatment of Chronic Lymphocytic Leukemia

Commack New York 11725

Patients are needed to participate in a clinical research study evaluating BTCT4465A and Obinutuzumab for the treatment of Lymphocytic Leukemia, Chronic or Lymphoma, Non Hodgkin

New York New York 10065

A clinical trial seeking patients for a research study for the treatment of Chronic Lymphocytic Leukemia

North Carolina

Duke University Medical Center
Durham North Carolina

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Ohio

Ohio State University Comprehensive Cancer Center
Columbus Ohio

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

View More ▼

Columbus Ohio 43210

A clinical trial seeking patients for a research study for the treatment of Chronic Lymphocytic Leukemia

Pennsylvania

Maryland Oncology Hematology PA
Gettysburg Pennsylvania

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Abramson Cancer Center of The University of Pennsylvania
Philadelphia Pennsylvania

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Tennessee

Nashville Tennessee 37203

A clinical trial seeking patients for a research study for the treatment of Chronic Lymphocytic Leukemia

Nashville Tennessee 37203

Patients are needed to participate in a clinical research study evaluating BTCT4465A and Obinutuzumab for the treatment of Lymphocytic Leukemia, Chronic or Lymphoma, Non Hodgkin

Texas

MD Anderson Cancer Center
Houston Texas

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Texas Tech University HSC University Medical Center
Lubbock Texas

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Scott and White Healthcare
Round Rock Texas

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

View More ▼

Houston Texas 77030

A clinical trial seeking patients for a research study for the treatment of Chronic Lymphocytic Leukemia

Virginia

University of Virginia
Charlottesville Virginia

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Washington

Northwest Medical Specialties
Gig Harbor Washington

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Medical Oncology Associates
Spokane Washington

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Swedish Medical Center
Washington Washington

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Australia

St Vincent's Hospital Sydney
Darlinghurst International

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Peter Maccallum Cancer Centre
East Melbourne International

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia